Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review
The Journal of Clinical Hypertension · 2024
DOI: 10.1111/jch.14924 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Hypertension, 2024. Verfasst von Wei Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hyper…. Hauptthemen laut MEDLINE: Hypertension, Anemia, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology, Shanghai Commissions of Science and Technology.
Abstract (Originalsprache)
Hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors are a new class of agents for the treatment of anemia in chronic kidney disease (CKD). Unlike traditional treatments such as erythropoiesis‐stimulating agents (ESAs), HIF‐PH inhibitors are orally administered drugs and may increase endogenous erythropoietin and improve iron homeostasis. However, a significant concern is their possible side effect on blood pressure. The current mini‐review summarizes the data of 26 randomized controlled (placebo or ESAs) trials on six different HIF‐PH inhibitors with regard to their potential influence on blood pressure and hypertension in the management of anemia in CKD. Overall, the use of HIF‐PH inhibitors was associated with a higher risk of hypertension than placebo (pooled risk ratio 1.36, 95% confidence interval [CI] 1.16–1.59), but a lower risk of hypertension than ESA treatment (pooled risk ratio 0.92, 95% CI 0.86–0.98), especially in CKD patients not undergoing dialysis (pooled risk ratio 0.85, 95% CI 0.73–0.98). This review highlights the importance of blood pressure monitoring during the treatment of HIF‐PH inhibitors, especially out‐of‐office blood pressure measurement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medi…
- National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Yan Li, Ji-Guang Wang
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology
- Shanghai Commissions of Science and Technology
Zitieren
APA
Zhang, W., Li, Y., & Wang, J. G. (2024). Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14924
Vancouver
Zhang W, Li Y, Wang JG. Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review. The Journal of Clinical Hypertension. 2024. doi:10.1111/jch.14924
BibTeX
@article{Zhang2024,
author = {Zhang, Wei and Li, Yan and Wang, Ji-Guang},
title = {Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review},
journal = {The Journal of Clinical Hypertension},
year = {2024},
doi = {10.1111/jch.14924}
}
EUVIMED